Apriliana E. R. Kartikasari

Dr. Apriliana E. R. Kartikasari

RMIT University, Melbourne, Victoria, Australia
orcid
Research Fellow at RMIT University

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 July 2021 in Frontiers in Oncology
Verified
Journal Article
Open access
PDF file
AKApriliana E. R. Kartikasari
Apriliana E. R. Kartikasari
CHCesar S. Huertas
Cesar S. Huertas
AMArnan Mitchell
Arnan Mitchell
Magdalena PlebanskiMagdalena Plebanski
Magdalena Plebanski
Chronic inflammation generated by the tumor microenvironment is known to drive cancer initiation, proliferation, progression, metastasis, and therapeutic resistance. The tumor microenvironment promotes the secretion of diverse cytokines, in different types and stages of cancers. These cytokines may inhibit tumor development but alternatively may contribute to chronic inflammation that supports tumor growth in both autocrine and paracrine manners and have been linked to poor cancer outcomes. Such distinct sets of cytokines from the tumor microenvironment can be detected in the circulation and are thus potentially useful as biomarkers to detect cancers, predict disease outcomes and manage therapeutic choices. Indeed, analyses of circulating cytokines in combination with cancer-specific biomarkers have been proposed to simplify and improve cancer detection and prognosis, especially from minimally-invasive liquid biopsies, such as blood. Additionally, the cytokine signaling signatures of the peripheral immune cells, even from patients with localized tumors, are recently found altered in cancer, and may also prove applicable as cancer biomarkers. Here we review cytokines induced by the tumor microenvironment, their roles in various stages of cancer development, and their potential use in diagnostics and prognostics. We further discuss the established and emerging diagnostic approaches that can be used to detect cancers from liquid biopsies, and additionally the technological advancement required for their use in clinical settings.

12 April 2013 in The EMBO Journal
Verified
Journal Article
Open access
PDF file
AKApriliana E. R. Kartikasari
Apriliana E. R. Kartikasari
JZJosie X Zhou
Josie X Zhou
MKMurtaza S Kanji
Murtaza S Kanji
DCDavid N Chan
David N Chan
ASArjun Sinha
Arjun Sinha
ABAnil Bhushan
Anil Bhushan
Stem cell differentiation depends on transcriptional activation driven by lineage‐specific regulators as well as changes in chromatin organization. However, the coordination of these events is poorly understood. Here, we show that T‐box proteins team up with chromatin modifying enzymes to drive the expression of the key lineage regulator, Eomes during endodermal differentiation of embryonic stem (ES) cells. The Eomes locus is maintained in a transcriptionally poised configuration in ES cells. During early differentiation steps, the ES cell factor Tbx3 associates with the histone demethylase Jmjd3 at the enhancer element of the Eomes locus to allow enhancer–promoter interactions. This spatial reorganization of the chromatin primes the cells to respond to Activin signalling, which promotes the binding of Jmjd3 and Eomes to its own bivalent promoter region to further stimulate Eomes expression in a positive feedback loop. In addition, Eomes activates a transcriptional network of core regulators of endodermal differentiation. Our results demonstrate that Jmjd3 sequentially associates with two T‐box factors, Tbx3 and Eomes to drive stem cell differentiation towards the definitive endoderm lineage.

1 May 2008 in Blood Cells, Molecules, and Diseases
Verified
Journal Article
Closed access
EKErwin H.J.M. Kemna
Erwin H.J.M. Kemna
AKApriliana E. R. Kartikasari
Apriliana E. R. Kartikasari
LTLambertus J.H. van Tits
Lambertus J.H. van Tits
PPPeter Pickkers
Peter Pickkers
HTHarold Tjalsma
Harold Tjalsma
DSDorine W. Swinkels
Dorine W. Swinkels

20 December 2005 in The FASEB Journal
Verified
Journal Article
Closed access
AKApriliana E. R. Kartikasari
Apriliana E. R. Kartikasari
NGNiki A. Georgiou
Niki A. Georgiou
FVFrank L. J. Visseren
Frank L. J. Visseren
HKHenny van Kats‐Renaud
Henny van Kats‐Renaud
BAB. Sweder van Asbeck
B. Sweder van Asbeck
JMJoannes J. M. Marx
Joannes J. M. Marx

1 December 2004 in Arteriosclerosis, Thrombosis, and Vascular Biology
Verified
Journal Article
Closed access
PDF file
AKApriliana E. R. Kartikasari
Apriliana E. R. Kartikasari
NGNiki A. Georgiou
Niki A. Georgiou
FVFrank L.J. Visseren
Frank L.J. Visseren
HKHenny van Kats-Renaud
Henny van Kats-Renaud
BAB. Sweder van Asbeck
B. Sweder van Asbeck
JMJoannes J.M. Marx
Joannes J.M. Marx
Objective— Elevated iron stores and high plasma iron concentration have been linked to an increased risk of atherosclerosis. Iron may thereby affect the interaction of monocytes to endothelium, an initial event in the formation of atherosclerotic plaques. Methods and Results— Addition of 10 μmol/L non–transferrin-bound iron to the incubation medium caused a 2-fold increase in monocyte adhesion to human umbilical vein endothelial cells (HUVECs). A concordant increase in the expression of the following adhesion molecules was observed: vascular cell adhesion molecule-1, intercellular adhesion molecule-1, and endothelial selectin on HUVECs as well as very late antigen-4, and lymphocyte function–associated antigen-1 on monocytes. The inclusion of either deferiprone or salicylaldehyde isonicotinoylhydrazone counteracted these effects. Intracellular iron chelation by deferoxamine was completed only after 10 hours of incubation, shown by reversal of iron-quenched intracellular calcein signal, and concurrently the effects of iron were blunted. The membrane-impermeable chelator, diethylenetriamine pentaaceticacid, failed to negate iron effects, even after 48 hours of treatment. Furthermore, only membrane-permeable superoxide or hydroxyl radical scavengers were capable of preventing HUVEC activation by iron. Conclusions— Non–transferrin-bound iron increases the level of intracellular labile iron, which promotes monocyte recruitment to endothelium and may thereby contribute to the pathogenesis of atherosclerosis. Iron-induced adhesion molecule expression was observed, and this event may involve the production of oxygen radicals. An increase in the level of intracellular labile iron induced monocyte adhesion to endothelium, an initial event in atherosclerotic plaque formation. A concordant increase in the cell adhesion molecule expression was observed. Furthermore, only inclusion of membrane-permeable iron chelators and radical scavengers resulted in a complete inhibition of these effects of iron.

25 January 2019 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
AKApriliana E. R. Kartikasari
Apriliana E. R. Kartikasari
MPMonica Prakash
Monica Prakash
MCMomodou Cox
Momodou Cox
KWKirsty Wilson
Kirsty Wilson
JBJennifer Boer
Jennifer Boer
Magdalena PlebanskiMagdalena Plebanski
Magdalena Plebanski
There is great interest in developing efficient therapeutic cancer vaccines, as this type of therapy allows targeted killing of tumor cells as well as long-lasting immune protection. High levels of tumor-infiltrating CD8+ T cells are associated with better prognosis in many cancers, and it is expected that new generation vaccines will induce effective production of these cells. Epigenetic mechanisms can promote changes in host immune responses, as well as mediate immune evasion by cancer cells. Here, we focus on epigenetic modifications involved in both vaccine-adjuvant-generated T cell immunity and cancer immune escape mechanisms. We propose that vaccine-adjuvant systems may be utilized to induce beneficial epigenetic modifications and discuss how epigenetic interventions could improve vaccine-based therapies. Additionally, we speculate on how, given the unique nature of individual epigenetic landscapes, epigenetic mapping of cancer progression and specific subsequent immune responses, could be harnessed to tailor therapeutic vaccines to each patient.